Back to News
Market Impact: 0.2
Kardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 Results
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & Outlook
Kardigan said its phase 2 trial of investigational drug ataciguat in aortic stenosis is fully enrolled. The company will assess the primary endpoint at 48 weeks rather than 24 weeks, with top-line results expected in the second half of 2027.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
KARD0.10
More News
- Kardigan, Inc. (KARD) Discusses Aortic Stenosis Progression Data and KATALYST-AV Baseline Findings Transcript
- Berkshire shares surge as Wall Street swoons amid AI fears
- CoreWeave seeks truce with Texas Governor-elect Hinojosa
- Seaport offers preliminary thoughts on Anthropic stock
- Forget tech and hide out in these stocks instead, Goldman Sachs says
- Alabama Power spent more than $6 million on ads last year — and customers can be billed for half of them until 2029